CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients – – Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses ...

Maelle has arguably the best collection of weapons to choose from in Clair Obscur: Expedition 33, such as Medalum, Lithum, ...

Omeros faces critical liquidity challenges, with limited cash runway and rising dilution risks. Its cash runway is ...

The Trump administration is planning a June 14 military parade to celebrate the 250th anniversary of the U.S. Army — and the ...

Detailed price information for Biomea Fusion Inc (BMEA-Q) from The Globe and Mail including charting and trades.

The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent ...

SENTI-202 is a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3 ...

LabPMM’s ultra-sensitive next generation sequencing FLT3 ITD MRD Assay provides clinicians with critical insights to tailor acute myeloid leukemia (AML) treatments and improve patient outcomes.

The fms-like tyrosine kinase 3 (FLT3) plays an important role in both normal and malignant hematopoiesis. Activating mutations in the FLT3 receptor can be detected in approximately 30% of acute ...

Back to Healio In this video, Catherine Lai, MD, MPH discusses the results of a study presented at ASH Annual Meeting that examined the use of FLT-3 inhibitors in leukemia patients with an FLT-3 ...

in adult patients aged 18 to 70 with newly diagnosed FLT3-ITD negative AML. Patients will be randomized 2:2:1 into three treatment arms. In Arms A and B, patients will receive VANFLYTA or placebo ...

BMF-500, an investigational, novel, orally bioavailable, highly potent and selective covalent small molecule inhibitor of FLT3, was discovered and developed in-house at Biomea using the company ...